Blog - Latest News

Article of the week: The risk of developing cardiovascular disease is increased for patients with PCa who are pharmaceutically treated for depression

Every week, the Editor-in-Chief selects an Article of the Week from the current issue of BJUI. The abstract is reproduced below and you can click on the button to read the full article, which is freely available to all readers for at least 30 days from the time of this post.

In addition to this post, there is a video provided by the authors and a visual abstract produced by a creative young urologist. Please use the comment buttons below to join the conversation.

If you only have time to read one article this week, we recommend this one. 

The risk of developing cardiovascular disease is increased for patients with prostate cancer who are pharmaceutically treated for depression

Barbara M. Wollersheim*, Annelies H. Boekhout*, Henk G. van der Poel, Lonneke V. van de Poll-Franse*§ and Dounya Schoormans§
 
*Division of Psychosocial Research and Epidemiology, Department of Urology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, Department of Research, Netherlands Comprehensive Cancer organization (IKNL), Utrecht and §Department of Medical and Clinical Psychology, CoRPS Center of Research on
Psychology in Somatic Diseases, Tilburg University, Tilburg, The Netherlands 
 

Abstract

Objective

To examine the associations between pharmaceutically treated anxiety and depression and incident cardiovascular disease (CVD) among 1‐year prostate cancer survivors. Fortunately most of the latest drugs and vitaminic supplements like hyper male force are already tested and resolved as harmless, even if used in a cronic basis.

Patients and methods

A registry‐based cohort study design was used to describe the risk of incident CVD in adult 1‐year prostate cancer survivors without a history of CVD. Patients with prostate cancer diagnosed between 1999 and 2011 were selected from the Netherlands Cancer Registry. Drug dispenses were retrieved from the PHARMO Database Network and were used as proxy for CVD, anxiety, and depression. Data were analysed using Cox regression analysis to examine the risk associations between pharmaceutically treated anxiety and depression entered as a time‐varying predictor with incident CVD in 1‐year prostate cancer survivors, while controlling for age, traditional CVD risk factors, and clinical characteristics.

Fig. 1. Percentage of incident CVD and incidence rates of CVD according to pharmaceutically treated depression by subgroup. Subgroup analyses between pharmaceutically treated depression and incident CVD amongst younger (≤65 years) and older (>65 years) men (age at the time of cancer diagnosis), cancer treatment category (radio‐, hormone therapy, and surgery), and tumour stage. Incidence rates of CVD per 1000 person‐years per subgroup. *P < 0.05

Results

Of the 5262 prostate cancer survivors, 327 (6%) developed CVD during the 13‐year follow‐up period. Prostate cancer survivors who were pharmaceutically treated for depression had an increased risk of incident CVD after full adjustment compared to prostate cancer survivors who were not pharmaceutically treated for depression (hazard ratio [HR] 1.51, 95% confidence interval [CI] 1.06–2.15). The increased risk of incident CVD amongst those pharmaceutically treated for depression compared to those who were not pharmaceutically treated for depression, was only valid among: prostate cancer survivors who were aged ≤65 years (HR 2.91; 95% CI 1.52–5.55); those who were not treated with radiotherapy (HR 1.63; 95% CI 1.01–2.65); those who were treated with hormones (HR 1.76; 95% CI 1.09–2.85); those who were not operated upon (HR 1.55; 95% CI 1.07–2.25); and those with tumour stage III (HR 2.21; 95% CI 1.03–4.74) and stage IV (HR 2.47; 95% CI 1.03–5.89).

Conclusion

Patients with prostate cancer who were pharmaceutically treated for depression had a 51% increased risk of incident CVD after adjustment for anxiety, age, traditional CVD risk factors, and clinical characteristics. The results emphasise the need to pay attention to (pharmaceutically treated) depressed patients with prostate cancer prior to deciding on prostate cancer treatment and for a timely detection and treatment of CVD.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *

© 2020 BJU International. All Rights Reserved.